Please login to the form below

Not currently logged in
Email:
Password:

Horizon adds AZ’s Galbraith to board

UK genomics company also appoints Susan Searle

Horizon Discovery has appointed two new board members, AstraZeneca's head of oncology R&D Susan Galbraith and Susan Searle, ex-CEO of Imperial Innovations Group.

Susan-Galbraith-Horizon

Galbraith is senior VP and head of oncology innovative medicines at AZ and knows Horizon well thanks to a collaboration between the two companies on personalised cancer treatments.

Targeted therapies were a point of note in a recent PMLiVE interview with Galbraith, where she also discussed the rise of immunotherapies and the potential of drug combinations.

Her past experience includes a period as VP of oncology and clinical biomarkers at Bristol-Myers Squibb.

Searle has a more entrepreneurial background, co-founding the technology venture investment business Imperial Innovations Group, where she spent 11 years as its CEO - during which time the company invested £120m in life science companies.

She also sits on the advisory board for the Technology Strategy Board's Emerging Technologies group.

Darrin Disley, CEO of Horizon, said of Galbraith and Searle: “Both have established highly successful careers in their chosen fields and also have proven leadership and advisory success.

“We believe each will be an invaluable asset to Horizon, and look forward to benefitting from their counsel.”

10th June 2014

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
KVA Digital

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics